Merck’s two-drug HIV regimen hits phase 3 success
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
Subscribe To Our Newsletter & Stay Updated